[1] Cao W, Hsieh E, Li TS. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges. Curr HIV/AIDS Rep 2020;17(1):26 − 34. http://dx.doi.org/10.1007/s11904-019-00478-xCrossRef
[2] Bertagnolio S, Hermans L, Jordan MR, Avila-Rios S, Iwuji C, Derache A, et al. Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy: a systematic review and meta-analysis. J Infect Dis 2021;224(3):377 − 88. http://dx.doi.org/10.1093/infdis/jiaa683CrossRef
[3] Kang RH, Liang SJ, Ma YL, Liang S, Xiao L, Zhang XH, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty 2020;9(1):54. http://dx.doi.org/10.1186/s40249-020-00668-5CrossRef
[4] World Health Organization. Surveillance of HIV drug resistance in adults initiating antiretroviral therapy (pre-treatment HIV drug resistance). 2014. http://apps.who.int/iris/bitstream/handle/10665/112802/9789241507196_eng.pdf?sequence=1. [2021-7-22].http://apps.who.int/iris/bitstream/handle/10665/112802/9789241507196_eng.pdf?sequence=1
[5] Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade FL, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis 2018;18(3):346 − 55. http://dx.doi.org/10.1016/S1473-3099(17)30702-8CrossRef
[6] Ávila-Rios S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV 2016;3(12):e579 − 91. http://dx.doi.org/10.1016/S2352-3018(16)30119-9CrossRef
[7] Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012;12(4):307 − 17. http://dx.doi.org/10.1016/S1473-3099(11)70255-9CrossRef